Diagnostic and therapeutic technology assessment. Vasoactive intracavernous pharmacotherapy for impotence: intracavernous injection of prostaglandin E1
The DATTA panelists consider PGE1 to be a useful addition to the family of
vasoactive agents used to treat organic impotence. It is associated with
fewer side effects than either papaverine or phentolamine. Although most
patients can achieve an erection with PGE1, some will not, and the other
vasoactive agents may be of benefit in these cases. Synergy has been
demonstrated when papaverine and PGE1 are used together, and a combination
of the two in reduced dosages may be effective in producing an erection
with a reduction in side effects. Intracavernosal therapy should be
prescribed and monitored by a urologist who is experienced in the treatment
of impotence and who is able to treat any of the potential side effects.
Whether long-term use of local injections will produce additional
complications is yet to be determined.
